Shares of Zosano Pharma (NASDAQ: ZSAN) soared more than 100% this morning on news that the company’s lead product candidate, M207, achieved both co-primary endpoints in the recently completed ZOTRIP trial. The ZOTRIP pivotal efficacy study compared three doses (1.0mg, 1.9mg and 3.8mg) of M207, a novel transdermal therapeutic, to placebo for a single migraine attack. The 3.8mg dose achieved significance in the secondary endpoints of pain freedom at 45 minutes and one hour and showed durability of effect on pain freedom at 24 and 48 hours. Overall, higher pain freedom rates were achieved on all doses after 60 minutes over placebo. Additionally, M207 was not associated with any Serious Adverse Events (SAEs). “ZOTRIP was designed to be a dose-ranging study, as well as a registration study. We are very pleased by the results for the 3.8mg dose, and look forward to continuing the development of M207 towards filing an NDA and working to bring this novel therapy to patients suffering from the incapacitating effects of migraines,” president and CEO of Zosano, Konstantinos Alataris, PhD, stated in the news release.
To view the full press release, visit: http://nnw.fm/zu4Fd
About Zosano Pharma
Zosano Pharma Corporation is an emerging CNS company focusing on providing rapid symptom relief to patients using known therapeutics and altering their delivery profile using the company’s proprietary intracutaneous delivery system. The company’s goal is to make intracutaneous drug delivery a standard of care for delivering drugs requiring fast onset of action. Zosano Pharma has developed its proprietary intracutaneous delivery system to administer proprietary formulations of existing drugs through the skin for the treatment of a variety of indications. The company believes that its intracutaneous delivery system offers rapid and consistent drug delivery combined with ease of use. The company is focused on developing products that deliver established molecules with known safety and efficacy profiles for markets where patients remain underserved by existing therapies. Zosano Pharma anticipates that many of its current and future development programs may enable the company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.NetworkNewsWire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer